Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 166 for “"Clopidogrel"”.
-
The vascular effects of clopidogrel
… thrombosis. The favored P2Y12 antagonist clopidogrel is a prodrug that is absorbed in the intestine and then converted into the active metabolite by cytochrome P450 enzymes (CYP450s). However, only about 5% of clopidogrel is converted into this active metabolite. The remainder is converted …
-
Interaction between proton pump inhibitors and clopidogrel
… (PPI) may impair the biotransformation of clopidogrel leading to increased major adverse cardiac events (MACE). Available studies have focused solely on patients receiving clopidogrel following a cardiac event. Given the widespread use of this combination, (about 64% in a recent study), …
-
Platelet Function Testing to Monitor Clopidogrel Therapy in Cats
… thromboembolism and other thrombotic events is clopidogrel, however resistance to its effects has been well documented. Determination of clopidogrel effect is traditionally inaccessible to primary care veterinarians. This thesis investigates methods of analysis of samples for determination of …
-
Clopidogrel reduziert die Entwicklung der Transplantat-Arteriosklerose im Mausmodell
… Dosierungen (1, 10 und 20 mg/kg) von Clopidogrel bzw. NaCl als Kontrolle. An den Tagen 2, 7, 14 und 30 wurden Blutanalysen in Form eines Thrombozyten-Aggregationstest mit Adenosin-Di-Phosphat (ADP) durchgeführt, um die Effektivität der Behandlung zu verfolgen. Die Transplantate wurden …
-
Post-P2Y₁₂-receptor signalling mechanisms and platelet responses to clopidogrel
Anti-aggregatory agents such as clopidogrel limit platelet responses to adenosine diphosphate (ADP) by blocking the P2Y₁₂ receptor and have pivotal roles in the prevention of coronary artery stent thrombosis. However anti-aggregatory responses to such agents vary between individuals and this may …
-
Clopidogrel Provision For Indigent Patients With St-elevation Myocardial Infarction
… does not take into account the long-term use of clopidogrel that is recommended by the American College of Cardiology and American Heart Association for patients that are treated with coronary stents. The purpose of this study was to evaluate outcomes of providing a short course of clopidogrel …
-
Die hemmende Wirkung von Clopidogrel auf die Aggregation humaner Thrombozyten
… recommend dual antiplatelet therapy with clopidogrel 75 mg qd and acetylsalicylic acid 100mg qd in patients undergoing elective coronary stent implantation. However, several studies demonstrated a high interindividual variability in antiplatelet response to clopidogrel with a significant …
-
Variabilität der Thrombozytenhemmung durch den ADP-Antagonisten Clopidogrel bei Patienten mit koronarer Herzerkrankung
… Variabilität bei der Therapie mit Clopidogrel wurden in dieser Promotionsarbeit Patienten mit ausreichender Therapiedauer auf eine verbleibende Aktivierbarkeit der Thrombozyten untersucht. Hierfür wurde eine auf Phosphorylierung des Proteins VASP basierender Assay, der mittlerweile …
-
Prevalencia de resistencia plaquetaria a clopidogrel en pacientes sometidos a intervencion coronaria percutanea
… multiple studies. In our study the prevalence of clopidogrel resistance by the method of platelet aggregometry Light transfer samples taken between 7 and 10 days post angioplasty, is about above the international average in our population, which warrants the implementation of new studies by the …
-
Combination of Clopidogrel and Montelukast may be Beneficial in the Management of Asthma
… the antiplatelet drugs, such as prasugrel, and clopidogrel, were found to inhibit the bronchial-hyperreactivity, platelet activation and eosinophil degranulation in animal studies and clinical trials. Therefore, we hypothesized that the combination of the antagonists to CysLTR1 (montelukast, …
-
Auswirkungen von Acetylsalicylsäure und Clopidogrel auf das Kollateralgefäßwachstum im zerebralen Arteriogenesemodell der Ratte
… Todesursachen. Acetylsalicylsäure (ASS) und Clopidogrel finden als Mono- oder Kombinationstherapien routinemäßigen Einsatz im Rahmen der Sekundärprävention. In dieser Studie wurden die Auswirkungen der anti-inflammatorischen Wirkungen von ASS gegenüber Clopidogrel auf die zerebrale …
-
Avaliação da expressão de miRNAs exossomais na toxicidade hepática induzida pelo clopidogrel em células HepG2
Clopidogrel is an essential therapy for prevention of thrombosis and atherosclerosis. However, clopidogrel-induced hepatotoxicity is a potential adverse effect related to liver damage and antiplatelet response. Considering the lack of diagnostic for this adverse effect, new exosomes-derived miRNAs …
-
Novel approach to assessment of efficacy of platelet inhibition by clopidogrel and aspirin in healthy dogs
… Introduction: Antiplatelet therapy, including clopidogrel and aspirin, is used to decrease the risk of thromboembolism in dogs. However, efficacy of therapy is not typically confirmed in clinical patients, nor is therapy able to be titrated to effect based on typical diagnostics. Methods: Six …
-
Antiplatelet response to aspirin and clopidogrel in patients with coronary artery disease undergoing percutaneous coronary intervention
Aspirin and clopidogrel are cornerstone therapies in cardiovascular disease. In particular, they are almost universally prescribed in patients undergoing percutaneous coronary intervention (PCI). Evidence has emerged of a variation in the antiplatelet effects of aspirin and clopidogrel between …
-
Inhibition der Thrombozytenfunktion durch eine Bolusdosis Clopidogrel und Prävalenz von Non-Respondern bei Patienten mit elektiver Koronarangiographie
Eine Vorbehandlung mit Clopidogrel vor einer koronaren Intervention senkt das Risiko periinterventioneller ischämischer Ereignisse. Zur Verkürzung des Zeitintervalls bis zum Eintritt der Wirkung wurde eine Bolusdosis von 600 mg Clopidogrel verwendet. Die hier vorliegende Studie untersuchte an …
-
Investigating the Risk of Adverse Cardiovascular Events Associated with Concomitant Treatment of Clopidogrel and Protein Pump Inhibitors
… (PPIs) are commonly coadministered with clopidogrel, an antiplatelet agent, to patients with acute coronary syndrome (ACS). Mechanistic studies suggest that PPIs have the potential to competitively inhibit the bioactivation of clopidogrel and may attenuate its antiplatelet action in the …
Page 1 of 9